Metronidazole 200mg Tablet Franchise in Ahmedabad

Antibacterial & Antiprotozoal Therapy Supplier in Mumbai

Metofoli 200 Tablet Distributor in Delhi

Gastrointestinal & Gynecological Infection Tablet Franchise Opportunity in Bangalore

Anaerobic Infection Tablet Stockist in Hyderabad
Metronidazole 200mg Export & Manufacturing in Chandigarh

Home/Products /metronidazole-200mg-tablet

Metofoli 200 Tablet

Composition : Metronidazole (200mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹1/-

Metofoli 200 Tablet contains Metronidazole 200mg, a widely used antibacterial and antiprotozoal agent indicated for treating infections caused by anaerobic bacteria and protozoa, including gastrointestinal and gynecological infections. It helps in reducing microbial load and controlling infection.

Metronidazole works by disrupting the DNA synthesis of susceptible microorganisms, leading to cell death and elimination of infection. Its targeted action ensures effective management of anaerobic bacterial and protozoal infections.

For distributors and healthcare suppliers, Metofoli 200 Tablet is a high-demand anti-infective product, commonly prescribed in hospitals, clinics, and outpatient departments. Its consistent requirement for gastrointestinal, gynecological, and parasitic infections ensures steady market demand.

Adding Metofoli 200 Tablet to your antibacterial and antiprotozoal therapy segment creates strong opportunities in pharmacies, hospitals, specialty clinics, export markets, and third-party manufacturing. Its proven efficacy, broad clinical usage, and prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.

Read More

About the Product

Metofoli 200 Tablet contains Metronidazole 200mg, a widely used antibacterial and antiprotozoal agent indicated for treating infections caused by anaerobic bacteria and protozoa, including gastrointestinal and gynecological infections. It helps in reducing microbial load and controlling infection.

Metronidazole works by disrupting the DNA synthesis of susceptible microorganisms, leading to cell death and elimination of infection. Its targeted action ensures effective management of anaerobic bacterial and protozoal infections.

For distributors and healthcare suppliers, Metofoli 200 Tablet is a high-demand anti-infective product, commonly prescribed in hospitals, clinics, and outpatient departments. Its consistent requirement for gastrointestinal, gynecological, and parasitic infections ensures steady market demand.

Adding Metofoli 200 Tablet to your antibacterial and antiprotozoal therapy segment creates strong opportunities in pharmacies, hospitals, specialty clinics, export markets, and third-party manufacturing. Its proven efficacy, broad clinical usage, and prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.

Common side effects may include nausea, vomiting, metallic taste, diarrhea, or mild abdominal discomfort. Rare but serious side effects include allergic reactions, seizures, peripheral neuropathy, or severe liver dysfunction. Patients should seek immediate medical attention if severe or persistent symptoms occur.

Metofoli 200 Tablet is indicated for the treatment of anaerobic bacterial infections, bacterial vaginosis, amoebiasis, giardiasis, trichomoniasis, and other protozoal infections as prescribed by a healthcare professional.

Before taking Metofoli 200 Tablet, inform your doctor if you have a history of liver disease, neurological disorders, or allergy to nitroimidazoles. The tablet should be taken as prescribed, completing the full course even if symptoms improve, to prevent recurrence or resistance. Alcohol should be avoided during therapy.

Store Metofoli 200 Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children and ensure the blister pack or container is intact. Do not use the tablet beyond its expiry date.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation